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Summary
Objective: Investigating the association between plasma levels of cytokines and chemokines, Selenoprotein S (SELS) gene variation and
osteoarthritis (OA) subtypes.
Methods: The genetics of osteoarthritis and progression (GARP) study consists of 191 sibling pairs with symptomatic OA at multiple joint sites.
We have measured plasma levels of 17 cytokines and chemokines and genetic variation at the SELS gene.
Results: Nine out of 17 serum markers could be assessed quantitatively, whereas eight markers were assessed qualitatively. Principal com-
ponent analysis (PCA) on the quantitatively assessed markers and serum high sensitive C-reactive protein (S-HsCRP) revealed that three
components underlie 61% of the total plasma variation. Three single nucleotide polymorphisms (SNPs) in the SELS gene revealed four com-
mon haplotypes, one of which, GAG (frequency 3.5%) showed signiﬁcant association to an anti-inﬂammatory (P¼ 0.019) and acute phase
related (P¼ 0.036) component. OA subtype analysis showed that one component (mainly representing chemokine variation) was signiﬁcantly
associated to hand OA and disc degeneration (P¼ 0.029 and P¼ 0.010 respectively) as well as a physical component score (PCS)
(P¼ 0.042). The CRP related component also showed a strong association to the PCS (P¼ 0.007). SELS haplotypes showed no association
to OA subtypes in the GARP study.
Conclusion: Genetic variation in the SELS gene associates to components representing inﬂammatory signaling. Another component, repre-
senting chemokine variation, showed association to hand OA and disc degeneration in the GARP study indicating chemokines may contribute
to OA pathogenesis.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) is a common joint disease and an impor-
tant cause of pain and disability in the general population.
Elucidation of common pathways that are involved in the
onset and progression of the disease will assist in the devel-
opment of new drug targets and provide a better manage-
ment of this disabling condition in the future. Several
studies have shown that genetic factors play an important
role in OA etiology1,2. Although OA is not regarded to be
an inﬂammatory disease, there is increasing evidence for
the involvement of an innate low grade systemic inﬂamma-
tory component which may partly explain the genetic sus-
ceptibility3e7. More speciﬁcally, support for the hypothesis
that local variation in cytokine levels in the joint may
inﬂuence OA onset and progression is found in the
catabolic effects of pro-inﬂammatory cytokines, and the
protective effects of anti-inﬂammatory cytokines in articular*Address correspondence and reprint requests to: Steffan D.
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621cartilage8,9. Gene expression studies have shown that in
OA cartilage several cytokines and chemokines are highly
expressed10e12. The recent introduction of multiplexed cy-
tokine assays facilitates sensitive measurements of differ-
ent cytokines using small amounts of valuable sample
material from different origins. This sensitive technique al-
lows investigation of the basal levels of chemokines and cy-
tokines in plasma in relation to the ongoing disease
processes for diseases where, as in OA, no pronounced
and obvious inﬂammatory component is present.
In a previous study, Curran et al. showed that subjects
can be characterized by a high (proinﬂammatory) or low
(noninﬂammatory) plasma cytokine proﬁle depending on
a common promoter single nucleotide polymorphism
(SNP) 105G>A (rs28665122) in the Selenoprotein S
(SELS) gene. A signiﬁcant association of this SELS SNP
was observed speciﬁcally with higher plasma levels of tu-
mor necrosis factor alpha (TNFa), interleukin beta (IL1b)
and interleukin 6 (IL6)13. SELS is a widely expressed pro-
tein involved in maintaining the functional integrity of the en-
doplasmatic reticulum (ER) by participating in the removal
of misfolded proteins and regulating the cellular redox
balance. SELS inhibition by small interfering RNA (siRNA)
revealed that a functionally impaired ER leads to activation
of numerous pro-inﬂammatory cytokines mediated by
622 S. D. Bos et al.: Cytokine, CRP & SELS gene variation in OAnuclear factor kb (NF-kb) activation13. In a cohort of patients
with intestinal inﬂammation, there was no association to the
SELS locus, however, the pro-inﬂammatory allele associ-
ated to a high serum CRP levels in Crohn Disease patients
with active disease14. Finally, SELS polymorphisms associ-
ated with coronary heart disease and ischemic stroke15.
These studies trigger the question whether SELS gene vari-
ation also inﬂuences inﬂammatory responses and the etiol-
ogy of OA. Hence, we set off to map the plasma levels of
17 cytokines and chemokines by use of a multiplexed bead
array system in subjects with symptomatic OAatmultiple joint
sites of the GARP study. We tested whether SELS gene var-
iation inﬂuenced these inﬂammatory plasma mediators and
OA, and whether these markers associated to OA subtypes
and severity.Materials and methodsTHE GARP STUDYThe GARP study consists of 191 sibling pairs. All participants have symp-
tomatic OA at multiple sites in the hand or OA at two or more joint sites of
four joint sites examined16. Symptomatic OA was determined following the
American College of Rheumatology recommendations17e19 whereas radio-
graphic OA (ROA) was scored according to Kellgren/Lawrence20. Details
on the GARP OA phenotype and inclusion criteria can be found in previous
publications16. Physical functioning was assessed with the physical compo-
nent score (PCS), a subscore of the Dutch validated RAND 36-item Health
Survey. This questionnaire covers health related aspects including social
functioning, role limitations, mental health and vitality21,22. A higher score
on the PCS indicates a better physical functioning. For the current study
we used the proportionate ROA score based on the presence of ROA at
each joint location and on the number of joints with ROA identical as de-
scribed previously. In short, scores 0, 1 and 2 represent respectively no,
uni- and bilateral hip and knee OA for these joint sites. The hand ROA score
(0e2) represents subjects with, respectively, 0e2, 3e6, and 7 hand joints
affected out of 20 scored. For spinal discus degeneration (DD) score (0e2)
represents subjects with DD at respectively 0e2, 3e5 and 6 levels out of
11 levels scored23. Hand OA following the American College of Rheumatol-
ogy (ACR) criteria17 was analyzed in addition to the ROA criteria. Genomic
DNA was extracted from peripheral blood leukocytes using standard
protocols. Written informed consent as approved by the ethical committee
was obtained from all subjects in the GARP study.SERUM AND PLASMA COLLECTION AND MEASUREMENTSFor each participant of the GARP study a morning serum and EDTA
plasma sample was collected. Samples were processed within 4 h upon
collection and stored at 80C until measurement. Serum high sensitive
C-reactive protein (S-HsCRP) was assayed earlier24. A 17-plex bead assay
provided by Bio-RAD was used to measure plasma levels of cytokines and
chemokines on a Luminex platform. Intra assay variation was estimated at
6.2%. The standard protocol was adjusted using twice the indicated amounts
of plasma sample in half the amount of sample buffer to increase signal in the
measurements. On each plate 10e15% of samples were in duplicate, in
which no inconsistencies were observed. For calculation of z-scores the
average value of duplos was used as a single value. For cytokines and
chemokines with less than 60% of the ﬂuorescence levels above background
noise, a qualitative measure of detectable vs not detectable level was used
(qualitative analysis, QL). For cytokines and chemokines with more than
60% ﬂuorescence levels above background noise, z-scores of ﬂuorescence
levels were calculated per plate (quantitative analysis, QT). In the principal
component analysis (PCA) individuals with missing values in ﬁve or more
out of nine cytokine/chemokines measurements were excluded (N¼ 13).
For the analyzed individuals remaining missing values were given the
speciﬁc marker mean score. Sample distribution was random per plate on
a total of eight plates.GENOTYPINGIn the current study three SNPs of the SELS were genotypes selected from
the original paper of Curran et al.13. SNP positions relative to translation start
of the SELS gene are105 (G> A, rs28665122),þ3705 (G> A, rs4965814),
andþ6218 (A>G, rs9874). SNPs were measured using hME chemistry on
a matrix assisted laser adsorption/ionization time-of-ﬂight mass spectrometry
Mass Spectrometer (Sequenom Inc., San Diego, CA, USA). Assays were de-
signed using the Sequenom MassARRAY Assay Design software (version3.1). Assay conditions were standard conditions as described earlier25. In ad-
dition to the genotypes obtained by the Sequenom for rs28665122, a Taqman
assay (Applied Biosystems, Foster City, California, United States) was
performed to deal with low genotyping success rates this SNP using the
Sequenom technique. Primers used for the ABI-genotyping were: forward
primer 50GGGTCGGCCTGCGA and reverse primer 50CTTCCGGTGCGC
TCCTA, probes were 50TGGCCGGGACCAC labeled with VIC and 50TTGGC
CAGGACCAC labeled with FAM. Assays were run on a 7900HT (Applied
Biosystems) according to the manufacturers speciﬁcations. Genotypes of
both techniques were used in addition to each other where necessary and
were used as a control where both techniques provided reliable genotypes.
No inconsistencies were observed between techniques for the reliable
genotypes.STATISTICAL ANALYSISPCA was applied to reduce the correlated data of the cytokines and che-
mokines plasma levels. Subjects (N¼ 341) with available levels of S-HsCRP
and with >4 out of nine quantiﬁable markers were entered in the PCA anal-
ysis. In PCA analyses random missing data (see Table II) was replaced by
mean values. Both empirical criteria (percentage of variance explained by
factors and Eigen values> 1) and interpretability were used to determine
the number of factors. We explored the interpretability of these factors after
applying a Varimax rotation with Kaiser Normalization. The loading score of
each variable onto the individual factors represents the contribution of that
variable to the variance observed in the resulting factor. For analysis only
individual variable contributions of >0.4 qualiﬁed for loading a component26.
A factor loading represents the linear relationship (Pearson correlation under
Varimax rotation) between a variable and a factor.
In order to assess the relationships between OA characteristics, genetic
variation at the SELS gene and the clusters of cytokines and chemokines,
a mixed model regression analyses was performed. To investigate the indi-
vidual associations, subject speciﬁc regression scores of each extracted
cluster were used as dependent variable and age, sex, BMI (Body Mass In-
dex) and all OA subtypes as co-variables. OA features and subtypes tested
were speciﬁc ROA scores as deﬁned previously; knee (0e2), hip (0e2),
hand (0e2) and spinal DD (0e2)24 and the PCS derived from the SF36 ques-
tionnaire. Furthermore, for each linear mixed model analysis family identity
numbers (representing family relations) as random variables in order to
model the familial dependencies that might occur for the levels.
Genotype distributions of SELS SNPs were checked by use of the HWE
program available at http://linkage.rockefeller.edu. Thesias V3.1 was used to
assess linkage disequilibrium between the SNPs and to assess the expected
haplotypic contribution to a mean quantitative measure in carriers of a spe-
ciﬁc haplotype27. Quantitative measures analyzed by use of Thesias are e.g.,
the subject speciﬁc regression scores as determined by the PCA analyses.
In individuals the expected quantitative measure is determined by the contri-
bution of the two carried haplotypes. The Thesias program allows for adjust-
ments of co-variables but not for familial relationship. Chi square analyses
were performed to test for association of individual SNPs or proportionate
ROA scores to the qualitatively analyzed cytokines and chemokines.
P-values are unadjusted to multiple testing. Analyses were done in SPSS
version 14 (SPSS, Chicago, IL, USA) unless mentioned otherwise.ResultsCYTOKINE AND CHEMOKINE MEASUREMENTSCharacteristics of the GARP study are displayed in
Table I. For all participants of the GARP study cytokine
and chemokine levels were analyzed in a plasma sample
by use of a 17-plex bead array system. Table II shows cy-
tokines and chemokines measured and the percentage of
samples with levels above detection limit. In nine instances
(see Table II) we were able to assess a semi quantitative
measure by the use of z-scores reﬂecting relative plasma
levels. For the remaining eight instances (see Table II),
plasma levels were analyzed in a qualitative matter (detect-
able vs not detectable).ASSOCIATION ANALYSIS OF CYTOKINE/CHEMOKINE
LEVELS WITH OA FEATURESNine cytokines and chemokines and S-HsCRP were an-
alyzed in a quantitative manner, the remaining eight cyto-
kines and chemokines were qualitatively analyzed. In the
Table I
Study characteristics of the 382 patients with OA at multiple joint
sites (GARP study)
N (%) Mean (sd) Range
Women 312 (81.7) e e
Age (years) 382 (100) 60.27 (7.54) 42.66e79.44
BMI (kgm2) 379 (99.2) 27.00 (4.67) 19.10e46.48
S-HsCRP (mgl1) 354 (92.7) 3.63 (5.43) 0.21e56.80
Clinical hand OA 271 (70.7) e e
PCS SF36 375 (98.2) 54.02 (21.10) 8.75e98.75
ROA score* 0 1 2
Knee 232 90 60
Hip 275 56 51
DD 125 181 76
Hand 169 110 103
PCS physical component score.
*All subjects were affected by OA at multiple joint sites. The
scores 0, 1 and 2 represent a proportionate OA score, as described
earlier24. In genetic analysis hip and knee replacements (respec-
tively 38 and 8) were considered as OA, numbers indicated are
patients with diseased joints at sampling, or had replacements
within the year prior to sampling.
Table III
Individual factor cytokine scores extracted by PCA of 10 inflamma-
tory markers measured in blood











Total variation explained 34.1% 15.7% 11.6%
*Extraction Method: PCA in which missing values were replaced
by mean levels.
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we observed substantial correlations (Supplementary Table
1). In addition to the association between S-HsCRP and
BMI shown previously24, Supplementary Table 1 also
shows the frequently observed association between BMI
and plasma IL6 levels. GARP subjects in the highest BMI
quartile (BMI> 29.1 kg/m2) had an OR of 1.7 (95% C.I.
1.01e2.82) to reside in the highest quartile of IL6 plasma
levels (P¼ 0.042) when corrected for age, sex and familial
relationship.
To reduce the redundancy between the markers to more
independent components in which these variables cluster,
a PCA including all inﬂammatory markers for which a quan-
titative measure was available (see Table II) and S-HsCRP
was performed. Table III shows the three components that
were extracted. The coefﬁcients depicted in Table III explain
how well each individual marker is represented within the
clusters. The marker levels of IL2, IL6, Granulocyte CSF
(GCSF) and IL10 loaded together on the ﬁrst component,Table II
Cytokines and chemokines in the 17-plex bead assay with levels
above background noise per cytokine and chemokine
Cytokine/Chemokine N Detectable (%) Analysis
Interleukin 1b 107 28.3 QL
Interleukin 4 26 6.9 QL
Interleukin 12 90 23.8 QL
Interleukin 13 172 45.5 QL
Interleukin 17 25 7.1 QL
Interferon g 179 47.4 QL
TNFa 165 43.4 QL
Granulocyte Monocyte CSF 144 37.8 QL
Interleukin 2 234 61.6 QT
Interleukin 5 222 58.4 QT
Interleukin 6 374 98.4 QT
Interleukin 7 274 72.1 QT
Interleukin 8 359 94.5 QT
Interleukin 10 327 86.1 QT
GCSF* 248 65.3 QT
MCP-1 377 98.9 QT
MIP-1b 375 98.4 QTexplaining 34.1% of the total variation in the GARP study.
Component 2 is determined by three chemokines MCP
(Monocyte Chemotactic Protein), IL8 and MIP (Macrophage
Inﬂammatory Protein), explaining 15.7% of the variation,
whereas the third component is determined by S-HsCRP,
IL5 and IL7 explaining 11.6% of the variation. It should be
noted that S-HsCRP has a negative value in the third com-
ponent (Table III), indicating that on average, within sub-
jects there is an inverse relation between S-HsCRP levels
and IL7 and IL5.
Subsequently the relationship between the three compo-
nents as dependant variables and the presence of OA char-
acteristics (Table I) as co-variables was investigated by
mixed model regression analysis. The upper section of
Table IV shows that component 2, consisting of chemo-
kines IL8, MIP and MCP, has signiﬁcant negative associa-
tions to hand ROA score (beta¼0.14 P¼ 0.039) and to
disc degeneration ROA score (beta¼0.22 P¼ 0.005),
independent of age, sex and BMI. This implies that subjects
with high chemokine levels have lower hand ROA and DD
scores. In addition, component 2 showed a similar associa-
tion to subjects that had hand OA according to the ACR
criteria (beta¼0.26; P¼ 0.024, data not shown). WhenTable IV
Effect sizes (b) of the linear relationships between the extracted
principal components (1e3) reflecting variation at plasma chemo-
kines/cytokine levels and OA characteristics (ROA score, clinical




Hip ROA score 0.079 0.098 0.035
Knee ROA score 0.079 0.043 0.088
Hand ROA score 0.030 0.140* 0.042
DD ROA score 0.002 0.223* 0.060
SF36 outcome
PCS 0.001 0.006* 0.007**
* P< 0.05 ** P< 0.01.
yComponent 1 contains IL2, GCSF, IL6, IL10 and IL7, Compo-
nent 2 contains MCP, IL8, MIP and component 3 contains S-
HsCRP (negative), IL5 and IL7. Data was analyzed using mixed
model regression analyses with the components as dependent vari-
able and as co-variables the joint speciﬁc ROA scores (top) or the
PCS (bottom) in addition to age, sex and BMI.
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derived from the SF36 a signiﬁcant negative association
of component 2 (P¼ 0.035) and a positive association to
component 3 (P¼ 0.004) was observed, independent of
sex, age and BMI (Table IV, lower section). This indicates
that subjects with high chemokine levels experience more
functional impairment whereas subjects with high IL7, IL5
and low S-HsCRP levels experience less functional impair-
ment. The association of PCS to component 2, however,
appeared not independent of the hand ROA scores (data
not shown). In each of the mixed models signiﬁcant associ-
ations with BMI were observed for component 1 (positive,
P¼ 0.049), for component 2 (negative, P< 1 105) and
component 3 (negative, P< 1 105). In the qualitatively
analysis of the cytokines no signiﬁcant associations were
observed for OA subtypes (data not shown).SELS GENE VARIATION, INFLAMMATORY
PARAMETERS AND OAIn the GARP study we could not conﬁrm the previously
reported association of rs28665122 with TNFa, IL1-b and
IL6 plasma levels by Curran et al.13.
The inﬂuence of the SELS SNPs on the cytokine and/or
chemokine levels, as expressed by the three components,
was investigated by haplotype analysis since high linkage
disequilibrium was observed between the three SELS
SNPs (D0 > 0.8). As shown in Table V, four common haplo-
types with frequencies over one percent were observed
similar to a Finnish population15. A signiﬁcant association
was observed between haplotype GAG (frequency 3.5%)
and component 1 (P¼ 0.019). Since component 1 reﬂects
variation in IL2, IL6, GCSF and IL10 levels this association
indicates that carriers of this haplotype have higher levels of
the cytokines in this component. Upon further investigation,
this association appeared to be mainly driven by IL10 vari-
ation (univariate analysis P¼ 0.001). In addition, the GAG
haplotype shows association to component 3 (P¼ 0.036)
containing IL5, IL7 and inversely S-HsCRP. This associa-
tion appeared to be mainly attributable to S-HsCRP levels
in the component (univariate analysis P¼ 0.002). These as-
sociations were independent of BMI, age and sex. The fact
that both components associate to the GAG haplotype indi-
cates some interrelation between the haplotype and these
components. We were not able to asses association be-
tween SELS SNPs or haplotypes and OA subtypes.Table V
Haplotype frequencies within the GARP study with their mean haplotypic c
cytokines/chemokin
Haplotype Number (%) C1*y mean (95% C.I.)
GGA 638 (83.5) 0.25 (0.61e0.11)
AAG 81 (10.6) 0.22 (0.65e0.20)
GAG 27 (3.5) 0.68 (0.24e1.10)z
GAA 10 (1.3) 0.68 (2.57e1.21)
Other 8 (1.1) e
Total 764 (100)
*Scores displayed are the expected haplotypic contribution (independe
score’’ of subjects calculated by the Thesias program. In individuals the e
lotypes. The THESIAS program does not allow correction for familial relat
105 (rs28665122G>A), þ3705 (rs4965814G>A), and þ6218 (rs9874
yComponent 1 reﬂects variation of IL2, IL6, GCSF, IL10 and IL7 levels
and component 3 reﬂects variation of HsCRP (negative), IL5 and IL7.
zBMI adjusted P-value <0.05 for contribution of the haplotype GAG
determined by THESIAS. C1 component 1, C2 component 2, C3 compoDiscussion and conclusion
In inﬂammation driven diseases high circulating plasma
levels of pro-inﬂammatory cytokines and S-HsCRP are
present well above detection limits of current methods
and readily used for diagnostic and prognostic purposes28.
Cytokines, however, are known to exert their wide ranged
actions also in very low concentrations. The recent introduc-
tion of multiplexed cytokine assays facilitates simultaneous
measurements of multiple cytokines. However, the de-
scribed absence of a large scale upregulation or strong as-
sociation of any of the measured cytokines or chemokines
in the plasma of subjects with familial OA at multiple joint
sites indicates that, in blood plasma, these markers are
not sufﬁciently suitable to monitor the ongoing OA process.
Synovial ﬂuid measurements might better reﬂect the ongo-
ing disease process since it better reﬂects the cytokine ac-
tivities near the site where the disease is mainly active29.
PCA analyses of cytokine/chemokines measurements re-
vealed 3 components. component 1 reﬂects variation at
IL2, IL6, GCSF and IL10 levels, component 2 reﬂects vari-
ation at chemokines MCP, IL8 and MIP and component 3 S-
HsCRP (negative), IL5 and IL7. The components seem to
reﬂect different ongoing (patho) physiological processes
identiﬁed by subjects underlying the components. Compo-
nent 1 may be classiﬁed as a marker of ongoing anti-inﬂam-
matory signaling based on the strong involvement of IL10,
whereas component 2 shows chemokine signaling and
component 3 reﬂects more acute phase related signaling.
The observed (Supplementary Table 1) and known correla-
tion of IL6 to S-HsCRP is, with the current setting in the
PCA (Eigen values> 1), not reﬂected in the components
since together they do not explain sufﬁcient amount of the
variation.
We found a signiﬁcant negative association for compo-
nent 2 to hand OA and DD as well as to the SF36 derived
PCS. This indicated that especially the subjects that exhibit
high functional impairment and have low hand ROA scores
have high chemokine levels. It should be noted that, by def-
inition of the GARP selection criteria, subjects of the GARP
study with low hand or disc ROA scores have OA at other
joint sites. We could not, however, attribute the negative as-
sociation of hand and disc ROA to positive effects caused
by these other joint sites. Given these results it appears
the higher levels of chemokines act protective in hand
and disc OA among subjects of the GARP study. The strong
association of the PCS to component 3 including S-HsCRPontribution to the component scores as extracted from the data of 9
es and CRP
C2*y mean (95% C.I.) C3*y mean (95% C.I.)
0.27 (0.58e0.05) 0.85 (0.56e1.15)
0.39 (0.79e0.00) 0.83 (0.48e1.18)
0.23 (1.06e0.61) 1.98 (1.35e2.61)*
0.37 (1.38e0.64) 0.92 (0.29e1.54)
e e
nt of the BMI effects) to the mean ‘‘principle component regression
xpected level is determined by the contribution of the 2 carried hap-
ionship. Alleles are in the following order of SNPs in the SELS gene
A>G).
, component 2 reﬂects variation of chemokines MCP, IL8 and MIP
to the component score as compared to the other haplotypes as
nent 3.
625Osteoarthritis and Cartilage Vol. 17, No. 5might reﬂect impairment of physical functioning mediated or
reﬂected by the individual markers in this component, the
observed effects are independent of BMI and ROA status.
Due to the relative large amount of missing values in the
IL5, IL7 and GCSF data we may have missed speciﬁc asso-
ciations with these markers.
Previously, it has been shown that there is a major upre-
gulation of chemokines in human OA affected cartilage12.
Our analysis show that, amongst subjects of the GARP
study, this upregulation might be less pronounced in sub-
jects with hand OA and disc degeneration of the spine as
compared to the other subjects, when correcting for all
involved joint sites. This may reﬂect a different pathophysi-
ological process underlying hand OA and disc degeneration
as compared to knee and hip OA. This needs to be further
explored in other cohorts of OA patients and especially us-
ing control samples.
Given the earlier found associations of SELS SNPs to in-
ﬂammatory factors measured in blood13, we expected to
ﬁnd associations of cytokines and chemokines especially
to rs28665122, however, no direct associations of these
levels or presence of these cytokines and chemokines
were observed for variation at the SELS gene. A recent pa-
per of Seiderer et al.14 also showed no conﬁrmation of the
association for rs28665122 to cytokine levels in a study in-
cluding patients with intestinal inﬂammation. As compared
to the study in intestinal inﬂammation patients, however,
Curran et al. used a more sensitive method of measuring
cytokines. Seiderer et al. did observe an association of
the pro-inﬂammatory allele to higher serum CRP levels in
a subgroup of Crohn disease patients with higher signs of
disease activity14. In our study, possibly the association to
either cytokines or S-HsCRP for rs28665122 is not ob-
served due to a smaller sample size or upregulation of
these cytokines by the ongoing disease processes is not
sufﬁcient to show the genotype effect as observed by
Seiderer et al.. However, haplotype association analyses
revealed a speciﬁc SELS haplotype (GAG, 3.5%) signiﬁ-
cantly associated to components of increased IL10 blood
levels and decreased S-HsCRP levels, conﬁrming that the
SELS gene variation may interfere with or affect the homeo-
stasis of the inﬂammatory pathways.
In the PCA individuals with missing values in ﬁve or more
out of nine cytokine/chemokines measurements were ex-
cluded (N¼ 13). For the analyzed individuals remaining
missing values were given the speciﬁc marker mean score.
Although we could not readily detect the cause of values
being missing most likely these occurred due to bad sample
quality or assay errors and less likely due to individuals being
out of range. Performing PCA using a list wise case selection
(using only cases with all markers available), replacing miss-
ing values by the lowest observed value, imputation of the
missing values by use of regression analysis or by use of
multiple imputation using a winMICE implemented expecta-
tion-maximization (EM) algorithm30 did not affect formation
of components or subsequent associations (data not
shown). The components reported should be considered
robust. The effect of the familial dependencies on the com-
ponent formation is considered to be minimal as the total
number of pairs in the dataset cancels out possible intra sib-
ling pair correlations. This is strengthened by the results of
an analysis of the data using only one member per sibling
pair (data not shown) which shows highly similar component
and scores.
Moreover, by excluding individuals with over four out of
nine missing values we may have excluded individuals
with a particular low-inﬂammatory proﬁle. Finally, missingvalues in the qualitatively analyzed cytokines may likewise
have been subject to possible misclassiﬁcation of individ-
uals due to bad sample quality, assay errors or measure-
ment problems.
Since OA patients are likely to use drugs which alter the
immune system we explored whether the use of NSAIDs
signiﬁcantly inﬂuenced our results. In a split analysis for
use vs no use of NSAIDs the formation of the components
in the PCA showed no major changes, except for the third
component in NSAID users where IL5 and IL7 disappeared.
The described subsequent associations remained present
in both separate datasets (data not shown).
In earlier investigations of the GARP study, we have
found that S-HsCRP levels are independently associated
to a CRP haplotype7,13 and by the occurrence of the closely
related factors knee ROA, BMI and high Western Ontario
and McMaster Universities Osteoarthritis Index (WOMAC)
scores24. In the current study we show that a SELS haplo-
type is additionally inﬂuencing the S-HsCRP level. When
we ﬁtted a mixed model with S-HsCRP as dependent vari-
able and as co-variables the CRP haplotype H7/8, SELS
haplotype GAG, and the factor representing knee ROA,
BMI and WOMAC24, it was shown that all three consistently
and independently inﬂuence the S-HsCRP level. In this
model, the SELS haplotype (GAG) signiﬁcantly decreased
(beta¼0.42; P¼ 1.9 105) S-HsCRP levels in carriers
whereas the S-HsCRP haplotype H7/8 (beta¼ 0.14;
P¼ 0.08) and the PCA component (beta¼ 0.14;
P¼ 1.6 109) increased S-HsCRP level.
The strength of the GARP study lies in the availability of
extended clinical and radiological data of OA features for
four joint sites. Furthermore, demographic data for the par-
ticipants is available, as well as additional familial informa-
tion, a range of biological ﬂuids and DNA. A downside for
this study is, however, that the sample size is relatively
small for genetic studies and no synovial ﬂuid samples
and control samples of healthy individuals are available
for the cytokine measurements in this study.
The analysis of a range of cytokines as measured in
blood has not shown any strong associations of one single
cytokine to OA features; however, a component comprised
of several chemokines did show association to OA in
smaller joints and PCS. Another component which has
strong involvement of S-HsCRP shows a highly signiﬁcant
association to this PCS, indicating physical impairment
might be reﬂected or mediated by the markers in this com-
ponent, independent of presence of speciﬁc ROA subtypes.
Future measurements of chemokines and related signaling
proteins in synovial ﬂuid may shed more light on the origin
of this association. Long term effects of lower circulating S-
HsCRP, cytokine or chemokine levels might be reﬂected by
OA progression. Upcoming follow up data in the GARP
study will reveal whether these inﬂammatory parameters
associate to further active progression of OA.Conﬂict of interest
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